Race Oncology Ltd has released a press release.
Letter to Shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race releases complete cardio-protection data & video
- Race releases cardioprotection market potential data
- Race Receives $1.48m R&D Tax Refund for Financial Year 2022
- Race Leadership Changes
- Pause in Trading
Later from Racura Oncology
- H1 2023 Preclinical and Clinical Programs Update
- Race global agreement with City of Hope to access FTO IP
- Race executes agreement with Ardena for GMP manufacturing
- Race Receives Additional $1.66m R&D Tax Refund for FY 2022
- Race Strategic Update August 2023
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology